Analyst Research

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Wright Reports
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Biogen Idec Inc Raises FY 2013 Guidance


Thursday, 25 Apr 2013 06:30am EDT 

Biogen Idec Inc updated its fiscal 2013 financial guidance. For fiscal 2013, the Company expects revenue growth to be approximately 16% to 18%, non-GAAP diluted EPS to be between $7.80 and $7.90 and GAAP diluted EPS to be between $6.69 and $6.79. The Company reported revenues of $5.5 billion in fiscal 2012. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $6.4 billion and EPS of $7.81 for fiscal 2013. 

Company Quote

343.36
0.37 +0.11%
27 Aug 2014